These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20142330)

  • 21. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
    Co NN; Iglesias D; Celestino J; Kwan SY; Mok SC; Schmandt R; Lu KH
    Cancer; 2014 Nov; 120(22):3457-68. PubMed ID: 25042259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
    Fong P; Meng LR
    Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cells expressing PAX8 are the main source of homeostatic regeneration of adult mouse endometrial epithelium and give rise to serous endometrial carcinoma.
    Fu DJ; De Micheli AJ; Bidarimath M; Ellenson LH; Cosgrove BD; Flesken-Nikitin A; Nikitin AY
    Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 32998907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.
    Andrade-Vieira R; Xu Z; Colp P; Marignani PA
    PLoS One; 2013; 8(2):e56567. PubMed ID: 23451056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the role of mTOR: lessons from mTOR inhibitors.
    Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
    Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
    Gao Y; Lin P; Lydon JP; Li Q
    J Pathol; 2017 Sep; 243(1):89-99. PubMed ID: 28657664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.
    Peña CG; Castrillón DH
    Adv Exp Med Biol; 2017; 943():211-241. PubMed ID: 27910069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting adhesion signaling in
    Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH; Hill CE; Rossi MR; Sica GL; Rupji M; Chen Z; Kowalski J; Kasinski AL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
    JCI Insight; 2017 Mar; 2(5):e90487. PubMed ID: 28289710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.
    Whang YM; Kim MJ; Cho MJ; Yoon H; Choi YW; Kim TH; Chang IH
    J Cell Physiol; 2019 Aug; 234(8):13083-13096. PubMed ID: 30549029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tumor suppressor kinase LKB1: lessons from mouse models.
    Ollila S; Mäkelä TP
    J Mol Cell Biol; 2011 Dec; 3(6):330-40. PubMed ID: 21926085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting LKB1 signaling in cancer.
    Korsse SE; Peppelenbosch MP; van Veelen W
    Biochim Biophys Acta; 2013 Apr; 1835(2):194-210. PubMed ID: 23287572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
    Seager CM; Puzio-Kuter AM; Patel T; Jain S; Cordon-Cardo C; Mc Kiernan J; Abate-Shen C
    Cancer Prev Res (Phila); 2009 Dec; 2(12):1008-14. PubMed ID: 19952358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LKB1 deletion with the RIP2.Cre transgene modifies pancreatic beta-cell morphology and enhances insulin secretion in vivo.
    Sun G; Tarasov AI; McGinty JA; French PM; McDonald A; Leclerc I; Rutter GA
    Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1261-73. PubMed ID: 20354156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction.
    Ikeda Y; Sato K; Pimentel DR; Sam F; Shaw RJ; Dyck JR; Walsh K
    J Biol Chem; 2009 Dec; 284(51):35839-49. PubMed ID: 19828446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.